SEC Form 3 · accession 0001615774-15-002893
ANAVEX LIFE SCIENCES CORP. · AVXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandra Boenisch
Officer — Principal Financial Officer
Period of report
Oct 1, 2015
Accepted (ET)
Oct 9, 2015 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314052
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | holding | — | — | — | 71,850 | D | ||
| Common stock | holding | — | — | — | 20,000 | I | By Estate of Roy James Rattenbury Testamentary Trust for Children of Sandra Boenisch |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.42 | holding | — | — | — | — | — | Common Stock | 100,000 | — | D |
Explanation of responses
- F1Ms. Boenisch holds options to purchase one hundred thousand (100,000) shares of common stock of Anavex Life Sciences Corp. at an exercise price of $1.42, said options to vest annually over a three year period commencing on December 31 2015.